Atezolizumab Regimen Fails to Extend PFS in Newly Diagnosed Ovarian Cancer

May 24, 2021 3:00 pm

By Jennifer Southall

The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study in Journal of Clinical OncologyRead more

Carboplatin Alone Not Adequate for Ovarian Cancer in Frail Seniors

April 27, 2021 6:00 pm

Worse survival than with combination carboplatin-paclitaxel regimens for vulnerable older patients with ovarian cancer.

For vulnerable older patients with ovarian cancer, single-agent carboplatin is less active, with worse survival, than combination carboplatin-paclitaxel regimens, according to a study published online April

Read more

HIPEC Combo Doubles PFS in Advanced Ovarian Cancer

March 26, 2021 12:00 pm

Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study.

By Charles Bankhead

Two drugs outperformed one for hyperthermic intraperitoneal chemotherapy (HIPEC) after interval surgical debulking of advanced ovarian cancer, data from a prospective registry showed.

Median progression-free survival (PFS) doubled … Read more

Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancer

March 21, 2021 5:00 pm

Responses in 37% of patients with AVB-500, higher without prior bevacizumab.

By Charles Bankhead

More than a third of patients with platinum-resistant ovarian cancer had objective responses to chemotherapy plus a small-molecule inhibitor that targets resistance-associated signaling, a preliminary study … Read more

Phase 3 OVAL Trial of VB-111 in Platinum-Resistant Ovarian Cancer Gets Green Light to Continue

February 24, 2021 6:00 pm

An independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.

By Courtney Marabella… Read more

Bevacizumab Beyond Disease Progression Plus Carboplatin-Based Doublet in Platinum-Sensitive Ovarian Cancer

February 23, 2021 6:00 pm

By Matthew Stenger

In the phase III MITO16b/MANGO–OV2/ENGOT–ov17 trial, investigators found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer who experienced disease … Read more

Immunotherapy Falls Short Again in Ovarian Cancer

September 23, 2020 6:00 pm

No PFS benefit in advanced disease with addition of atezolizumab to chemo, bevacizumab.

By Charles Bankhead

An immunotherapy boost failed to improve outcomes in newly diagnosed advanced ovarian cancer compared with chemotherapy and bevacizumab (Avastin), a large international trial showed.… Read more

HIPEC With Cytoreductive Surgery Effective in Ovarian Cancer

August 25, 2020 5:00 pm

By Sarah Williams

For patients with stage III epithelial ovarian cancer, adding hyperthermic intraperitoneal chemotherapy (HIPEC) to primary cytoreductive surgery (PCS) increases survival compared with PCS alone, according to results of a retrospective study now published in JAMA Network OpenRead more

Study Suggests QoL Assessments Do Not Support First-Line Combination Chemotherapy With Weekly Paclitaxel for Epithelial Ovarian Cancer

July 21, 2020 6:00 pm

By Susan Moench, PhD, PA-C

Results of quality of life (QoL) assessments from the randomized, phase 3 ICON8 study evaluating once-weekly vs thrice-weekly administration of paclitaxel in combination with carboplatin as first-line chemotherapy in patients with epithelial ovarian cancer do … Read more

WEE1 Kinase Inhibitor Improved PFS in TP53-Mutated Ovarian Cancer

July 8, 2020 5:00 am

Preclinical studies of adavosertib indicated that the drug increased sensitization of TP53-mutated cells to chemotherapy.

By Leah Lawrence

Adavosertib, a WEE1 kinase inhibitor, plus carboplatin and paclitaxel improved progression-free survival (PFS) in women with TP53-mutated, platinum-sensitive ovarian cancer compared … Read more

Weekly Dose-Dense Chemo Not Recommended in First-Line Epithelial Ovarian Cancer Treatment

December 20, 2019 6:00 pm

By Matthew Fowler

Weekly dose-dense paclitaxel as a frontline treatment for patients with epithelial ovarian cancer was not found to significantly improve progression-free survival (PFS) compared to the standard 3-weekly chemotherapy, according to results from the ICON8 study published in … Read more

PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Cancer?

September 29, 2019 6:00 pm

By Ed Susman

PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines.

Patients with newly diagnosed advanced ovarian cancer who responded to first-line chemotherapy, then were treated with niraparib (Zejula), had a significantly reduced risk … Read more

Benefit of Single-Agent Carboplatin in Vulnerable, Elderly Patients With Ovarian Cancer

June 5, 2019 7:00 pm

By Leah Lawrence

Single-agent carboplatin conferred significantly worse survival outcomes in vulnerable, elderly patients with stage III/IV epithelial ovarian cancer compared with weekly or every 3 weeks carboplatin/paclitaxel, according to results of the EWOC-1 trial (abstract 5508), which … Read more

Study Shows Ovarian Cancer Survival Increase

May 3, 2019 5:00 pm

A gynecologic oncologist at the Stephenson Cancer Center at OU Medicine was a national leader of a newly published research study that reveals good news for women with ovarian cancer—longer survival times plus a treatment option that causes fewer difficult … Read more

Still No Benefit of IP Chemo for Ovarian Cancer

April 24, 2019 5:00 pm

By Charles Bankhead

No PFS or OS benefit, more toxicity with IP verses IV regimens

Final results of a highly anticipated randomized trial failed to show a survival benefit with intraperitoneal (IP) chemotherapy in patients with newly diagnosed advanced ovarian … Read more

Early Data Send Strong Signal in Advanced Gyn Cancers

March 19, 2019 7:00 pm

By Ian Ingram

Clinical benefit rate tops 90% in pair of single-center studies.

Two early trials of novel combinations showed promising clinical activity in gynecologic cancers at a late-breaking abstract session at the Society of Gynecologic Oncology (SGO) meeting here.… Read more

Lenvatinib Combo Yields Favorable Responses in Ovarian, Endometrial Cancers

March 18, 2019 3:30 pm

By Kristie L. Kahl

Lenvatinib (Lenvima) in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, resulting in a 65% overall response rate (ORR), according to results from a phase I study presented … Read more

Alisertib-Based Combo Improves Survival Outcomes in Ovarian, Breast Cancer

January 21, 2019 10:30 am

By Jessica Skarzynski

For some time now, paclitaxel has been considered standard of care in the treatment of patients with platinum-resistant ovarian cancer; however, recent research has shown the addition of the investigational drug alisertib to a paclitaxel regimen demonstrated … Read more

Drug Combination Gives ‘Exciting’ Results in Ovarian and Lung Cancer in Early Trial

August 24, 2018 1:58 am

Combining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.

The combination of targeted drug vistusertib along with paclitaxel chemotherapy … Read more

Tumor Treating Fields Plus Paclitaxel Appears Safe, Effective in Recurrent Ovarian Cancer

August 16, 2018 12:57 am
BY Kristie L. Kahl
The combination use of Tumor Treating Fields (TTFields) and paclitaxel more than doubled progression-free survival (PFS) in patients with recurrent, platinum-resistant ovarian cancer compared with those who received weekly paclitaxel, according to results from the phase … Read more